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Abstract 
 
Background 
 
Studying the phenotypic manifestations of increased genetic liability for Bipolar 
Disorder (BD) can increase understanding of this disorder.  
 
Aims 
 
We assessed whether genetic risk for BD was associated with childhood 
psychopathology and features of hypomania in young adulthood within a large 
population-based birth cohort. 
 
Methods 
 
We used data from the second Psychiatric Genetics Consortium Genome Wide 
Association Study (GWAS) for Bipolar Disorder to construct a polygenic risk score 
(PRS) for each individual in the Avon Longitudinal Study of Parents and Children 
(ALSPAC). Linear and logistic regression models were used to assess associations 
between the BD-PRS and emotional/behavioural difficulties, attention deficit 
hyperactivity disorder (ADHD) and borderline personality disorder (BPD) traits in 
childhood, as well as hypomania in early adulthood (sample sizes from 2,654 to 
6,111).  
 
 
Results 
 
The BD-PRS was not associated with total hypomania score, but was weakly 
associated with a binary measure of hypomania (OR=1.13, 95%CI 0.98,1.32; 
p=0.097), and particularly at higher hypomania symptom thresholds (strongest 
evidence OR=1.33, 95%CI 1.07, 1.65; p=0.01). The BD-PRS was also associated 
with ADHD (OR=1.31, 95%CI 1.10, 1.57; p=0.018), but not with other childhood 
psychopathology.  
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Limitations  
 
The PRS only captures common genetic variation and currently explains a relatively 
small proportion of the variance for BD. 
 
Conclusions 
 
The BD-PRS was associated with ADHD in childhood, and weakly with adult 
hypomania, but not with other psychopathology examined. Our findings suggest that 
genetic risk for BD does not appear to manifest in childhood to the same extent as 
schizophrenia genetic risk has been reported to do.  
 
Key words ALSPAC, ADHD, Polygenic Risk Score, Bipolar Disorder, Hypomania 
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1. Introduction 
 
Bipolar disorder (BD) is a common psychiatric disorder (Cross-Disorder Group of the 
Psychiatric Genomics, 2013) with a lifetime risk of 1-2% (Merikangas et al., 2011). 
Difficulties in accurate diagnosis during the early course of BD contribute to a 
substantial illness burden to the individual and society (Connell et al., 2012; 
Marwaha et al., 2013; Park et al., 2013).  
 
Hypomanic/manic episodes that are required for a diagnosis of BD rarely manifest 
before age 25 years (Leboyer et al., 2005), although depressive episodes frequently 
precede these, and sometimes by as much as 10 years before a diagnosis of BD, 
rather than unipolar depression, becomes apparent (Fritz et al., 2017). Individuals 
with BD often have a history of psychopathology in childhood/adolescence that is 
broader than just depression (Duffy et al., 2010; Topor et al., 2013). For example, 
Attention Deficit Hyperactivity Disorder (ADHD), conduct problems and hyperactivity 
in childhood have been associated with a greater risk for developing BD 
(Donfrancesco et al., 2011; Henin et al., 2007; Singh et al., 2014). Borderline 
personality disorder (BPD) has also been associated with increased risk for 
developing BD, and is often present co-morbidly in adults with BD (Fornaro et al., 
2016; Parker et al., 2016). Furthermore, whilst manic episodes rarely occur before 
young adulthood, sub-threshold hypomanic symptoms may occur much earlier than 
the first diagnosis of BD and may be useful for predicting both BD onset 
(Fiedorowicz et al., 2011) and conversion from depression to BD (Tijssen et al., 
2010).  
 
Whilst the phenomenological overlap and high rates of comorbidity between the 
psychopathology described above and BD may be due to shared genetic heritability 
(Cross-Disorder Group of the Psychiatric Genomics, 2013; Witt et al., 2017), it is 
currently not known how genetic risk for BD manifests during childhood, 
adolescence, and early adulthood in the general population (Mistry et al., 2018). 
Understanding this is important as it could help inform the identification of individuals 
who are most at risk of developing BD, and minimise misdiagnosis and incorrect 
treatment (Ghaemi et al., 1995; Hirschfeld and Vornik, 2004; Keck et al., 2008). 
5 
 
 
BD has a heritability of approximately 60-85% (Craddock and Sklar, 2013), and 
Genome Wide Association Studies (GWASs) have identified a number of single 
nucleotide polymorphisms (SNPs) that occur more frequently in BD cases relative to 
controls (Bipolar Disorder and Schizophrenia Working Group of the Psychiatric 
Genetics Consortia, 2018; Cross-Disorder Group of the Psychiatric Genomics, 2013; 
Sklar et al., 2011; Stahl et al., 2017). One method to examine the effect of multiple 
SNPs on disease risk is the polygenic risk score (PRS) approach, which provides 
biologically valid indicators of disease risk for research (Cross-Disorder Group of the 
Psychiatric Genomics, 2013; Purcell et al., 2009). Although individual risk SNPs 
have small effects on disease risk, taken together alleles on current GWAS platforms 
explain approximately 4% of the genetic variation for BD on the liability scale (Bipolar 
Disorder and Schizophrenia Working Group of the Psychiatric Genetics Consortia, 
2018; Cross-Disorder Group of the Psychiatric Genomics, 2013; Ikeda et al., 2017; 
Stahl et al., 2017). 
 
In this study we therefore used the polygenic risk score (PRS) approach to assess 
whether genetic risk for BD, calculated using the largest GWAS on BD to date (Stahl 
et al., 2017), was associated with childhood psychopathology or features of 
hypomania assessed in early adulthood within a large, population-based birth cohort 
study, the Avon Longitudinal Study of Parents and Children (ALSPAC). 
 
 
6 
 
2. Methods  
 
2.1 Participants 
 
ALSPAC (www.bris.ac.uk/alspac/) was set up in April 1991. Mothers of children born 
in the South West of England (Avon) between 1st April 1991 and 31st December 
1992 (Boyd et al., 2013) were invited to take part. The initial cohort contained 15,445 
participants (Boyd et al., 2013) with extensive baseline information from the first 
trimester of pregnancy onwards. Data were collected regularly at defined time 
intervals and is ongoing. The study website contains details of all the data, 
searchable through the data dictionary (www.bris.ac.uk/alspac/researchers/data-
access/data-dictionary/). This study received ethical approval from the ALSAPC Law 
and Ethics Committee and Local Research Ethics Committees 
(http://www.bristol.ac.uk/alspac/researchers/research-ethics/). 
 
2.2 Hypomania 
 
When the cohort were 22-23 years of age, postal and online questionnaires for 
assessing lifetime history of hypomanic symptoms, using the Hypomania Checklist-
32 (HCL-32) were sent. In total, 9,359 participants were invited to complete the HCL-
32, of whom 3,448 (37%) returned the questionnaire. The HCL-32 has been used 
extensively in clinical and non-clinical settings and is validated as a screening tool for 
BD type II (Angst et al., 2011; Forty et al., 2009; Holtmann et al., 2009; Meyer et al., 
2014).  
 
A previous study conducted a Rasch analysis for unidimensionality of the HCL-32 
and identified four items as redundant and could be excluded (Court et al., 2014). 
Therefore, in our study, we have used these 28 items to derive our outcomes:  
 
i) Hypomania symptom score: Our primary outcome of hypomania that 
reflected the total HCL score (range 0 to 28), which was then 
standardised. 
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ii) Hypomania: Our secondary outcome of hypomania was a binary outcome 
defined as meeting a threshold score on the HCL of ≥14/28, in addition to 
having symptoms for a duration of 2-3 days or more (to satisfy the ICD-10 
criteria for hypomania to have lasted for “at least several days”), and a 
response of either negative, or both negative and positive impact of highs 
on family life, social life, work life or leisure. Whilst a score of ≥14/28 yields 
the best sensitivity and specificity in clinical samples (Fornaro et al., 2015; 
Mosolov et al., 2014; Perugi et al., 2012; Wu et al., 2008), higher threshold 
cut off scores, indexing a greater degree of psychopathology, will likely 
capture individuals who are most likely to have ‘clinically-relevant’ 
hypomania.  We therefore also examined, as sensitivity analyses, binary 
measures of hypomania defined by HCL scores of ≥16/28, ≥18/28, ≥20/28, 
≥22/28 and ≥24/28 to explore whether results are consistent irrespective of 
how we define the outcome, and if not, how they change as we alter the 
cut-off threshold 
iii) Hypomania factors: Other secondary outcomes were latent factors relating 
to a) ‘energy/mood’ and b) ‘risk-taking/irritability’ that have previously been 
derived (An et al., 2011; Fornaro et al., 2015; Hantouche et al., 2003; 
Meyer et al., 2007), and confirmed in this sample (Mistry et al., 2017). 
 
2.3 Emotional and behavioural difficulties 
 
We used the Strengths and Difficulties Questionnaire (SDQ) that was completed by 
parents when their children were aged 9 years as a measure of emotional and 
behavioural difficulties (Goodman, 1997). We examined associations between the 
PRS and the SDQ total difficulties score (which was standardised), and, as 
secondary analyses, with scores for the 5 SDQ subscales (hyperactivity problems, 
prosocial behaviour, emotional difficulties, conduct problems and peer relationship 
difficulties), in a sample of 6,111 children.  
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2.4 Assessment of childhood ADHD  
 
At age 91 months (7.6 years), the presence of ADHD was assessed in 8,219 
children using the Development and Wellbeing Assessment (DAWBA), based on 
parent ratings (Goodman et al., 2000). This assessed the presence of psychiatric 
disorders including DSM-IV ADHD, rated as absent or present. Whilst presence of 
any ADHD sub-type (inattentive, hyperactive-impulsive, or combined) was our 
primary outcome, we also examined as a secondary analysis whether associations 
were stronger for one sub-type compared to another. 
 
2.5 Assessment of borderline personality disorder (BPD) traits 
 
At age 11 years, the cohort was interviewed to assess their experience of BPD traits 
over the preceding two years. The interview was conducted by trained psychologists, 
using the Childhood Interview for DSM-IV Borderline Personality Disorder (CI-BPD). 
This is a semi-structured interview designed to assess BPD traits in latency-age 
children and adolescents, adapted for use in this cohort (Zanarini et al., 2004) . The 
CI-BPD is based on the borderline module of the Diagnostic Interview for DSM-IV 
Personality Disorders (Zanarini et al., 1996). The convergent validity of the CI-BPD 
has been shown by findings that this measure is significantly associated with 
clinician diagnosis and other measures of BPD reported by patients and parents 
(Sharp et al., 2012). It contains nine BPD traits (anger symptoms, affective instability, 
emptiness, identity disturbance, paranoid ideation, abandonment, suicidal behaviour, 
impulsivity and intense interpersonal relationships). Judgements were made by a 
trained assessor and rated as absent, probably present or definitely present (coded 
as 0, 1 and 2 respectively). To meet criteria for definitely present, the trait had to be 
present at least 25% of the time (or daily). A probably rating required the trait to be 
present regularly but not as often as definitely.  
 
We derived a BPD traits score by summing the 9 individual BPD traits (range from 0-
18) and standardised this score. Furthermore, individuals in the present study were 
classified as being ‘high risk for borderline personality disorder’ if they were rated 
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‘probably’ or ‘definitely’ on 5 or more of the nine items, as used previously (Wolke et 
al., 2012). 
 
2.6 Genetics 
 
Genetic data from 9,912 participants were obtained using the genome wide single-
nucleotide polymorphism genotyping platform (HumanHap550-Quad; Illumina). 
GWAS data were generated by Sample Logistics and Genotyping Facilities at 
Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using 
support from 23andMe. Following quality control, imputation, and restriction to 1 
young person per family, genetic data were available on 8,230 individuals (see 
Supplementary methods available online for more detail). 
 
Prior to construction of the PRS, SNPs were removed from the analysis if their 
imputation quality (INFO) score was <0.8, had a minor allele frequency (MAF) of 
<0.01 or if there was a mismatch of alleles between the PGC and ALSPAC.  
 
2.7 Polygenic Risk Scores (PRS) 
 
The PRS for BD was constructed using summary statistics from the second 
Psychiatric Genetics Consortium Bipolar Disorder (PGC-BD) Genome Wide 
Association Study (GWAS) (Stahl et al., 2017). The PGC study, containing 
information on risk alleles and their corresponding effect sizes, was used to generate 
a PRS for each individual in ALSPAC.  
 
SNPs were clumped using PLINK v1.90 using the --clump command. The PRS was 
derived using r2 <0.2 within 1MB windows , and using SNPs with a PT≤0.5 (Sklar et 
al., 2011) (our primary exposure threshold for all outcomes), and additionally a 
PT≤0.01 (the threshold that maximally captures BD liability) (Stahl et al., 2017) for 
our hypomania outcomes. 
  
The PRS for each individual in ALSPAC was calculated using the --score command 
on PLINK. To generate the score, the sum of the total number of risk alleles present 
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for each SNP (0, 1, 2) was weighted by the log of its odds ratio (OR) for BD from the 
PGC. The ALSPAC sample has been shown to have no significant population 
stratification, and genome-wide analyses of phenotypes indicate a low lamda (Martin 
et al., 2015; Zammit et al., 2014). Therefore, we did not adjust for population 
stratification using principle components analysis. 
 
2.8 Statistics 
 
Logistic regression was used to determine associations between the BD-PRS and 
hypomania, ADHD and being ‘high-risk’ for borderline personality disorder. These 
results are presented as odds ratios (ORs) per standard deviation (SD) increase in 
PRS. Linear regression was used to determine associations between the BD-PRS 
and hypomania symptoms score, hypomania latent factors, SDQ scores and 
borderline personality disorder traits score. These results are presented as SD 
change in outcome per SD increase in PRS. R2 values (and Naglekarke r2 for 
logistic) are reported as a measure of the variance in outcome explained by the 
PRS. Data were analyzed using STATA statistical software (version 14.1 SE. 
College Station, TX: StataCorp LP). 
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3. Results  
 
3.1 Sample characteristics 
 
Of the 8,230 ALSAPC individuals whose genetic data passed quality control checks 
(51.2% male), 2,654 to 6,111 participated in the assessments used from age 7 to 23 
years (Table 1).  
 
Insert Table 1 
 
3.2 BD-PRS and hypomania 
 
The BD-PRS was not associated with higher hypomania symptom scores (p=0.336). 
However, there was very weak evidence the BD-PRS was associated with increased 
odds of being classified as having hypomania at the threshold cut off score of ≥14/28 
(OR=1.13, 95%CI 0.98, 1.32; p=0.097) at PT≤0.5 (Table 2).  
 
Insert Table 2 
 
When using higher threshold cut-off scores on the HCL to define hypomania, we 
found stronger evidence that a higher BD-PRS was associated with increased odds 
of having hypomania, with strongest evidence at an HCL score cut-off threshold of 
≥20/28 (OR=1.33, 95%CI 1.07, 1.65; p=0.01) (Supplementary Table 1). 
 
The BD-PRS was not associated with either the ‘energy/mood’ (p= 0.292), or ‘risk-
taking/irritability’ factors (p=0.572) (Table 2). 
 
Evidence of association with hypomania symptom scores, hypomania factors, and 
hypomania at the threshold cut off score of ≥14/28 was weaker at a PT of ≤0.01, 
whereas the association with hypomania at the threshold cut off score of ≥20/28 was 
very similar to that for PT≤0.5 (Supplementary Tables 2 & 3). 
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3.3 BD-PRS and other psychopathology 
 
There was strong evidence that the BD-PRS was associated with increased odds of 
being diagnosed with ADHD (OR=1.31, 95%CI 1.10, 1.57; p=0.003) (Table 3). 
Additionally, we were interested in whether associations were more strongly 
associated with a specific type of ADHD. We found evidence of association with 
inattentive ADHD (OR=1.37, 95%CI 1.06, 1.79; p=0.018), but not hyperactive-
impulsive or combined ADHD, though confidence intervals for all subtypes 
overlapped substantially (Supplementary Table 4). 
 
We found no evidence the BD-PRS was associated with the SDQ total difficulties 
score (p=0.302), nor with the individual SDQ subscales: hyperactivity (p=0.760), 
prosocial behaviour (p=0.951), emotional difficulties (p=0.175), conduct problems 
(p=0.131) and peer relationship difficulties (p=0.231) (Table 3). 
 
There was no evidence of association between the BD-PRS and the BPD traits 
score (p=0.898) and similarly no evidence of an association between the BD-PRS 
and being classed as ‘high-risk’ for borderline personality disorder (p=0.860) (Table 
3). 
 
Insert Table 3   
13 
 
4. Discussion  
 
4.1 Summary of findings 
 
Within this large population-based birth cohort, we found no evidence of association 
between the BD-PRS and hypomania symptom score or the hypomania factors. 
There was very weak evidence of association between the BD-PRS and a binary 
measure of hypomania, though evidence was stronger when greater symptom 
number counts were required to be classed as having hypomania.  
 
There was strong evidence of an association between the BD-PRS and ADHD, but 
no evidence for association with SDQ scores, BPD traits score or being ‘high-risk’ for 
BPD. 
 
4.2 Findings in the context of previous work 
 
4.2.1 BD-PRS and hypomania  
 
We are unaware of previous studies examining genetic risk for bipolar disorder and 
hypomania as an outcome per se. Two studies have examined whether the BD-PRS 
can discriminate those with BD-I compared to those with BD-II, though these studies 
reported inconsistent results (Aminoff et al., 2015; Charney et al., 2017). 
 
The BD-PRS is derived from a GWAS of clinical samples of individuals with bipolar 
disorder (Sklar et al., 2011; Stahl et al., 2017), who would have more severe 
psychopathology than those who meet criteria for hypomania in our sample. This 
may explain why evidence of association with hypomania in our study was weaker 
than for studies that have reported the ability of the BD-PRS to predict BD case 
status in clinical samples (Charney et al., 2017; Power et al., 2015; Schulze et al., 
2014; Tesli et al., 2014). Whilst we did find evidence of association with hypomania 
in our sensitivity analysis, this needs to be interpreted in the context of testing a 
number of hypomania outcomes defined at different score thresholds. Overall 
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therefore, our findings suggest that measures of hypomania in the young adult 
general population do not strongly reflect the influence of genetic risk for BD. 
 
 4.2.2 BD-PRS and SDQ 
 
We have previously shown that the SDQ subscales for hyperactivity and conduct 
problems are associated with “dark-side” hypomania (Hantouche et al., 2003) as 
indexed by the ‘risk-taking/irritability’ factor in our study (Mistry et al., 2017). We 
therefore expected the BD-PRS to be associated with the SDQ, but this was not the 
case. A possible reason for our lack of finding associations between genetic risk for 
BD and the SDQ might be related to the completion of the SDQ by the parents. It is 
possible the behavioural problems the children were experiencing may have been 
underestimated by some of the parents, which could lead to greater measurement 
error. This could result in associations being relatively underpowered for this 
phenotype, though the SDQ is a well validated measure of childhood 
psychopathology (Goodman, 1997). It is also possible that genetic risk for BD is not 
expressed as any of the broad range of psychopathologies measured by the SDQ. 
 
To our knowledge, only one other study has examined whether genetic risk for BD is 
associated with childhood psychopathology. Using data from the Generation R 
cohort, the authors reported the BD-PRS (using the PGC-1-BD GWAS summary 
statistics) was not associated with externalising or internalising scales on the Child 
Behaviour Checklist (CBCL) in children at ages 3, 6 and 10 years (Jansen et al., 
2018). Our study, though the first to examine the association of childhood 
psychopathology with the most recent PGC-2-GWAS of BD is consistent with these 
findings.  
 
4.2.3 BD-PRS and ADHD  
 
Comorbidity between ADHD and BD along with symptom overlap between these 
disorders has been well documented (Singh et al., 2006). Age of onset of diagnosed 
BD (Sachs et al., 2000) and first presentation of affective symptoms (Ryden et al., 
2009) are significantly earlier in those who have a history of childhood ADHD 
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compared to those without childhood ADHD. However, a narrative review of 
prospective cohort studies of the offspring of parents with BD reported that a clinical 
diagnosis of childhood ADHD was not a reliable predictor of future development of 
BD (Duffy, 2012), although the studies included in this review (9 in total) had low 
numbers of participants within each study (7 – 216 individuals). We have previously 
shown that a diagnosis of ADHD was associated with the ‘risk-taking/irritability’ factor 
of hypomania, though this association may not be with bipolar disorder per se (Mistry 
et al., 2017). 
 
Our findings are consistent with several studies reporting the BD-PRSs ability to 
discriminate ADHD cases from controls (Hamshere et al., 2013; Schimmelmann et 
al., 2013). However, it is important to acknowledge the extent of shared genetic 
heritability between BD and ADHD is small, evidenced by a relatively small 
proportion of the variance in ADHD explained by the BD-PRS (Cross-Disorder Group 
of the Psychiatric Genomics, 2013). Our study suggests that genetic risk for BD 
might manifest more as inattention rather than hyperactivity/impulsivity in childhood, 
although our findings are also compatible with similar effect sizes for the different 
ADHD subtypes. There is some evidence that symptoms of hyperactivity and 
impulsivity tend to decline with age whilst inattention typically persists (Faraone et 
al., 2015), and our findings might therefore reflect a greater genetic (including cross-
disorder) contribution to the inattentive ADHD subtype.   
 
Our finding of stronger evidence of association between genetic risk for bipolar 
disorder and ADHD, compared to genetic risk for BD and hypomania, could be the 
result of how these measures were assessed in the ALSPAC cohort. ADHD was 
assessed using the DAWBA, a questionnaire completed by the parents, whilst the 
HCL-32 was a self-report questionnaire. ADHD diagnosis was based on DSM-IV 
criteria whilst our measure of hypomania in this study is based on a symptom score 
threshold with evidence of impaired function, so is more loosely related to DSM-IV 
criteria for bipolar II disorder. It is possible that the DAWBA is a more accurate 
measure of assessing for ADHD than the HCL-32 is for assessing hypomania, and 
that measurement error for the latter is greater. The weak evidence overall of 
association between high genetic risk for BD and our binary measures of hypomania 
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suggests the HCL does not accurately index individuals with high propensity to 
developing BD. 
 
4.2.4 BD-PRS and BPD traits 
 
At the present time, genetic research on BPD is limited. These mainly focus on 
candidate genes and involve small sample sizes (Calati et al., 2013). A case-control 
study examined the association between BD risk variants and BPD case status, and 
reported a weak association between the SNP rs1006737 in CACNA1C and BPD 
(Witt et al., 2014). More recently, Witt et al., (2017) conducted the first GWAS of 
borderline personality disorder and found evidence of genetic overlap (genetic 
correlation of 0.28) between the BD-PRS and BPD (Witt et al., 2017).  
 
We did not find evidence of a higher BD-PRS in individuals with higher BPD traits 
scores, or in those classed as ‘high-risk’ for BPD. Our measure of BPD traits in this 
sample is likely to capture a much less severe phenotype than that present in cases 
from the GWAS by Witt et al (2017) (Witt et al., 2017). Furthermore, whilst we 
defined a group of children at age 11 years as being ‘high-risk’ for borderline 
personality disorder, a reliable diagnosis of BPD at this age is not possible and we 
had no data to determine how many of these individuals who were classed as ‘high-
risk’ would eventually meet criteria for this diagnosis in adulthood. This might explain 
the apparent inconsistency of our findings with those from Witt et al., (2017), though 
our results nevertheless indicate that borderline personality disorder traits in 
childhood are not manifest as a consequence of high genetic risk for BD. These 
results also suggest that associations between BPD traits in childhood and adult 
hypomania, as we reported recently (Mistry et al., 2017) is unlikely to be confounded 
by shared genetic effects, and might perhaps be more likely explained by shared 
environmental risk such as childhood trauma (McDermid et al., 2015). 
 
4.3 Strengths and limitations 
 
Our study has a number of strengths. Firstly, we used the largest and most recent 
Bipolar Disorder GWAS from the PGC as the training set (PGC-2-BD) (Stahl et al., 
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2017), thus minimising measurement error. Second, we used a large, well 
characterised population-based sample for assessing our phenotypes of interest. All 
phenotypes, excluding hypomania outcomes, were assessed in childhood, at an age 
where it might be most useful to detect early manifestations of bipolar disorder. 
Third, we used well validated measures to assess our phenotypes, making 
information bias in our results less likely.  
 
However, there are also a number of limitations. Firstly, scores on the HCL do not 
reflect a DSM-IV/ICD-10 diagnosis of BD. However, the score may be used to 
assess propensity to BD, particularly in a group of individuals where first onset of 
manic symptoms is unlikely to have occurred at age 22/23 years (Leboyer et al., 
2005). Missing data in our sample could lead to selection bias. Whilst sample 
representativeness is critical for estimating prevalence, empirical and simulation 
studies have demonstrated that selection bias does not usually affect interpretation 
of results of associations between exposures and outcomes (Howe et al., 2013; Pizzi 
et al., 2011; Wolke et al., 2009), though we cannot be certain that our results are not 
affected by the extent of missing data (Ebrahim and Smith, 2013). 
 
Finally, whilst GWAS capture effects on risk conferred by common variants, they are 
unable to detect effects of rare variants, thus our results reflect only common variant 
influences on childhood/young adulthood outcomes.   
 
4.4 Conclusions 
 
Within this large, prospective population-based birth cohort, we found associations 
between increased genetic risk for bipolar disorder and increased odds of ADHD and 
less robustly with hypomania, but not with other psychopathology.  
 
Genetic risk for BD might not be manifest until later in development (in contrast to 
schizophrenia genetic risk where there is evidence of association with childhood 
psychopathology) (Nivard et al., 2017).  
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Further work in large, population-based longitudinal studies could explore whether 
phenotypic expression of genetic risk for bipolar disorder changes with age, and 
determine the utility of combining polygenic risk scores with other measures, such as 
presence of childhood psychopathology, for predicting risk of developing bipolar 
disorder.  
 
Insert Supplementary Tables 1, 2, 3 and 4 
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1 
 
Genetic data 
 
Genetic data from 9,912 participants were acquired using the Illumina 
HumanHap550 quad genome-wide single nucleotide polymorphism (SNP) 
genotyping platform. GWAS data were generated by Sample Logistics and 
Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory 
Corporation of America) using support from 23andMe. Individuals were excluded 
from further analysis on the basis of minimal or excessive heterozygosity, gender 
mismatch, disproportionate levels of individual missingness (>3%), evidence of 
cryptic relatedness (>10% of alleles identical by descent (IBD)), and being of non-
European ancestry (assessed by multidimensional scaling analysis including 
HapMap 2 individuals). SNPs with a minor allele frequency (MAF) of < 1%, Impute2 
information (INFO) score < 0.8, a call rate of < 95% or evidence for violations of 
Hardy-Weinberg equilibrium (p< 5 x 10-7) were removed. Imputation of the target 
data was performed using Impute V2.2.2 against the 1000 genomes reference panel 
(Phase 1, Version 3; all polymorphic SNPs excluding singletons), using 2186 
reference haplotypes (including non-Europeans). Following quality control 
assessment and imputation and restricting to 1 young person per family, genetic 
data was available for 8230 ALSPAC individuals 
 
  
 
2 
 
Table 1. Table showing individuals with outcome number 
 
 
 
HCL; Hypomania Checklist, SDQ; Strengths and Difficulties Questionnaire, ADHD; 
Attention Deficit Hyperactivity Disorder, DAWBA; Development and Wellbeing 
Assessment, CI-BPD; Childhood Interview for DSM-IV Borderline Personality 
Disorder
Outcome Measure Data source Age (years) Measure type 
N (% with 
outcome if 
binary) 
HCL score 
HCL-28 
 22-23 
Standardised 
score 2,654 
Threshold HCL cut 
off score ≥14/28 
Binary 
outcome 2,654 (7) 
Energy/mood 
factor 
Standardised 
score 2,654 Risk-
taking/irritability 
factor 
Total difficulties 
score SDQ 9 
Standardised 
score 6,111 
ADHD DAWBA 7.6 Binary outcome 6,105 (2) 
Borderline 
personality 
disorder traits 
score 
CI-BPD 11 Standardised score 5,246 
3 
 
Table 2. Associations between the BD-PRS and hypomania outcomes 
 
 
 
BD-PRS; Bipolar Disorder-Polygenic Risk Score, HCL; Hypomania Checklist; OR; 
Odds Ratio; PT; P-value threshold 
Exposure Outcome N 
N with 
outcome 
if binary 
(%) 
β 95%CI P R2 (%) 
BD-PRS at 
PT≤0.5 
HCL score 2654  0.02 -0.02, 0.06 0.336 0.03 
Energy/mood 
factor 
2363 
 0.02 -0.02, 0.06 0.292 0.05 
Risk-
taking/irritability 
factor 
 0.01 -0.03, 0.05 0.572 0.01 
Exposure Outcome N 
N with 
outcome 
if binary 
(%) 
OR 95%CI P R2 (%) 
BD-PRS at 
PT≤0.5 
Threshold 
≥14/28 2654 239 (7.1) 1.13 0.98, 1.32 0.097 0.20 
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Supplementary Table 1. Results of sensitivity analyses using different threshold 
cut-off scores on the HCL 
 
Exposure Outcome N 
N with 
outcome 
if binary 
(%) 
OR 95%CI P R2 (%) 
BD-PRS 
at 
PT≤0.5 
Threshold 
≥14/28 
2654 
239 (7.1) 1.13 0.98, 1.32 0.097 0.20 
Threshold 
≥16/28 198 (5.9) 1.14 0.97, 1.34 0.105 0.22 
Threshold 
≥18/28 150 (4.4) 1.20 1.00, 1.44 0.053 0.38 
Threshold 
≥20/28 101 (3.0) 1.33 1.07, 1.65 0.01 0.89 
Threshold 
≥22/28 60 (1.8) 1.34 1.02, 1.76 0.036 0.86 
Threshold 
≥24/28 34 (1.0) 1.09 0.76, 1.56 0.645 0.06 
 
HCL; Hypomania Checklist, BD-PRS; Bipolar Disorder-Polygenic Risk Score, PT; P-
value threshold, CI; Confidence Interval 
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Supplementary Table 2. Associations between the BD-PRS and hypomania 
outcomes 
 
 
Exposure Outcome N 
N with 
outcome 
if binary 
(%) 
β 95%CI P R2 (%) 
BD-PRS at 
PT≤0.01 
HCL score 2654  0.0001 -0.04, 0.04 0.998 0 
Energy/mood 
factor 
2363 
 0.01 -0.03, 0.05 0.546 0.02 
Risk-
taking/irritability 
factor 
 -0.01 -0.04, 0.03 0.747 0 
Exposure Outcome N 
N with 
outcome 
if binary 
(%) 
OR 95%CI P R2 (%) 
BD-PRS at 
PT≤0.01 
Threshold 
≥14/28 2654 239 (7.1) 1.07 0.92, 1.24 0.382 0.06 
 
BD-PRS; Bipolar Disorder-Polygenic Risk Score, HCL; Hypomania Checklist; OR; 
Odds Ratio; PT; P-value threshold 
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Supplementary Table 3. Results of sensitivity analyses using different threshold 
cut-off scores on the HCL 
 
Exposure Outcome N 
N with 
outcome 
if binary 
(%) 
OR 95%CI P R2 (%) 
BD-PRS at 
PT≤0.01 
Threshold 
≥14/28 
2654 
239 (7.1) 1.07 0.92, 1.24 0.382 0.22 
Threshold 
≥16/28 198 (5.9) 1.08 0.92, 1.27 0.348 0.07 
Threshold 
≥18/28 150 (4.4) 1.13 0.94, 1.36 0.193 0.17 
Threshold 
≥20/28 101 (3.0) 1.32 1.06, 1.64 0.013 0.83 
Threshold 
≥22/28 60 (1.8) 1.24 0.94, 1.64 0.120 0.47 
Threshold 
≥24/28 34 (1.0) 1.12 0.78, 1.61 0.541 0.11 
 
HCL; Hypomania Checklist, BD-PRS; Bipolar Disorder-Polygenic Risk Score, PT; P-
value threshold, CI; Confidence Interval 
 
 
 
 
 
 
Table 3. Association between the BD-PRS and other childhood psychopathologies 
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Exposure Outcome N β 95%CI P R2 
BD-PRS at 
PT<0.5 
Hyperactivity 
problems 6,134 -0.004 -0.03, 0.02 0.760 0 
Prosocial 
behaviour 6,138 -0.001 -0.03, 0.02 0.951 0 
Emotional 
difficulties 6,117 0.02 -0.01, 0.04 0.175 0.03 
Conduct 
problems 6,133 0.02 -0.01, 0.04 0.131 0.04 
Peer 
relationship 
difficulties 
6,128 0.02 -0.01, 0.04 0.231 0.02 
Total 
difficulties 
score 
6,111 0.11 -0.01, 0.04 0.302 0 
BPD traits 
Outcome N β 95%CI P R2 (%) 
BPD traits 
score 5,246 0.002 -0.03, 0.03 0.898 0 
Outcome N (% with outcome) OR 95%CI P R
2 (%) 
‘High risk’ 
for BPD 5,247 (5.8) 1.01 0.90, 1.13 0.860 0 
DSM-IV ADHD 
Outcome N (% with outcome) OR 95%CI P R
2 (%) 
ADHD 6,105 (7) 1.31 1.10, 1.57 0.003 0.73 
 
BD-PRS; Bipolar Disorder-Polygenic Risk Score; PT; P-value threshold; BPD; 
Borderline Personality Disorder, ADHD; Attention Deficit Hyperactivity Disorder
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Supplementary Table 4. Associations between the BD-PRS and types of ADHD 
 
 
BD-PRS; Bipolar Disorder-Polygenic Risk Score, ADHD; Attention Deficit 
Hyperactivity Disorder, PT; P-value threshold, CI; Confidence Interval 
 
 
 
 
 
 
 
 
 
 
Exposure Outcome N (% with outcome) OR 95%CI P R
2 (%) 
BD-PRS at 
PT≤0.5 
Inattentive 
ADHD 
6,102 
(0.85) 1.37 1.06, 1.79 0.018 0.88 
Hyperactive-
impulsive 
ADHD 
6,102 
(0.30) 1.44 0.91, 2.30 0.119 0.99 
Combined 
ADHD  
6,102 
(0.97) 1.19 0.90, 1.57 0.230 0.25 
